Literature DB >> 28735071

Fulminant response to combined checkpoint inhibition with ipilimumab plus nivolumab after failure of nivolumab monotherapy in metastatic melanoma.

Selma Ugurel1, Felix Kiecker2, Stefan Fröhling3, Axel Wetter4, Agnes Bankfalvi5, Antje Sucker6, Lisa Zimmer6, Elisabeth Livingstone6, Alexander Roesch6, Jürgen C Becker7, Dirk Schadendorf6.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28735071     DOI: 10.1016/j.ejca.2017.06.020

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  1 in total

1.  Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy.

Authors:  Valerie Glutsch; Franziska Grän; Judith Weber; Anja Gesierich; Matthias Goebeler; Bastian Schilling
Journal:  J Immunother Cancer       Date:  2019-07-12       Impact factor: 13.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.